Last reviewed · How we verify
NCT03344887: iTADS
An Innovative Trial Assessing Donor Sex on Recipient Mortality
Phase 4 trial testing RBC Transfusion from male donor in Red Blood Cell Transfusion in 8,850 participants. Status unknown.
23 January 2021
Quick facts
| Lead sponsor | Ottawa Hospital Research Institute |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 8,850 |
| Start date | 4 September 2018 |
| Primary completion | 23 January 2021 |
| Estimated completion | 1 December 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- RBC Transfusion from male donor
- RBC Transfusion from female donor
Conditions studied
- Red Blood Cell Transfusion — all drugs for Red Blood Cell Transfusion →
Sponsor
Ottawa Hospital Research Institute
Who can join
28 Days and older, any sex, with Red Blood Cell Transfusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The iTADS trial will test an important blood donor characteristic - donor sex - to see whether male donor blood leads to a greater benefit for transfusion recipients compared to female donor blood. The trial will help determine how the investigators can tailor the selection of blood donors based on donor characteristics (e.g. sex) to further improve the safety and optimize the clinical benefit of blood products in Canada.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effect of Donor Sex on Recipient Mortality in Transfusion.
Chassé M, Fergusson DA, Tinmouth A, Acker JP, et al · · 2023 · cited 18× · PMID 37043654 · DOI 10.1056/nejmoa2211523 -
Pragmatic, double-blind, randomised trial evaluating the impact of red blood cell donor sex on recipient mortality in an academic hospital population: the innovative Trial Assessing Donor Sex (iTADS) protocol.
Fergusson DA, Chassé M, Tinmouth A, Acker JP, et al · · 2021 · cited 10× · PMID 33622960 · DOI 10.1136/bmjopen-2021-049598
Verify or expand the search:
- PubMed search for NCT03344887
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ottawa Hospital Research Institute trials
Trials by the same sponsor.
- NCT07464080 — Advanced Brain Imaging-TKA (fMRI-TKA) · NA · recruiting
- NCT07171567 — Vacuum Therapy for the Treatment of Penile Numbness/Sensory Changes · EARLY_PHASE1 · recruiting
- NCT07058025 — Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants · Phase 2 · not yet recruiting
- NCT07177833 — Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease · Phase 1 · recruiting
- NCT06929767 — Do Blood Tests Help to Decide Which Patients With Flares of Chronic Obstructive Pulmonary Disease (COPD) Need Antibiotic · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03344887 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ottawa Hospital Research Institute
- Last refreshed: 16 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03344887.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing